Related Experiment Video
Updated: Jun 12, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
[Myocardial protection against global ischemia-reperfusion with use of Krebs-Henseleit buffer-based cardioplegic
Insights
A new Krebs-Henseleit buffer cardioplegic solution offers improved myocardial protection against ischemia-reperfusion injury during heart surgery. Tested in rat hearts, it showed better results than standard solutions, warranting further preclinical investigation.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Biochemistry
Context:
- Myocardial protection during cardiopulmonary bypass is critical for cardiac surgery outcomes.
- Global ischemia-reperfusion injury poses a significant risk to the heart.
- Standard cardioplegic solutions require optimization for enhanced efficacy.
Purpose:
- To evaluate a novel Krebs-Henseleit buffer-based cardioplegic solution.
- To assess its effectiveness in myocardial protection during global ischemia-reperfusion.
- To compare its performance against standard cardioplegic solutions in normothermic and hypothermic conditions.
Summary:
- A new crystalloid cardioplegic solution based on Krebs-Henseleit buffer was tested in an isolated rat heart model.
- In normothermic conditions (37°C), this solution demonstrated superior myocardial protection compared to standard solutions.
- Evidence includes reduced infarct size and improved left ventricular functional recovery post-ischemia.
Impact:
- The Krebs-Henseleit buffer-based cardioplegic solution shows promise for clinical application.
- It may offer enhanced myocardial protection in cardiac surgery patients.
- Further preclinical studies are recommended to validate these findings for broader use.
Abstract:
Improvement of myocardial protection against global ischemia-reperfusion injury during cardiopulmonary bypass remains to be of primary importance for cardiac surgery. In the present study, the effectiveness of new Krebs-Henseleit buffer-based cardioplegic solution was investigated in an isolated rat heart preparation in normo- and hypothermic states. Use of this crystalloid cardioplegic solution in the normothermic mode (37 degrees C) resulted in better myocardial protection in comparison to standard cardioplegic solutions as evidenced from both infarct size data and the patterns of left ventricular postischemic recovery. The data obtained indicate that Krebs-Henseleit buffer-based cardioplegic solution might be recommended for further preclinical testing.
